Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice.

The lipid transport protein apolipoprotein E (apoE) is abundantly expressed in the brain. Its main isoforms in humans are apoE2, apoE3, and apoE4. ApoE4 is the major known genetic risk factor for Alzheimer's disease and also contributes to the pathogenesis of various other neurological conditions. In the central nervous system, apoE is synthesized by glial cells and neurons, but it is unclear whether the cellular source affects its biological activities. To address this issue, we induced excitotoxic injury by systemic kainic acid injection in transgenic Apoe knockout mice expressing human apoE isoforms in astrocytes or neurons. Regardless of its cellular source, apoE3 expression protected neuronal synapses and dendrites against the excitotoxicity seen in apoE-deficient mice. Astrocyte-derived apoE4, which has previously been shown to have detrimental effects in vitro, was as excitoprotective as apoE3 in vivo. In contrast, neuronal expression of apoE4 was not protective and resulted in loss of cortical neurons after excitotoxic challenge, indicating that neuronal apoE4 promotes excitotoxic cell death. Thus, an imbalance between astrocytic (excitoprotective) and neuronal (neurotoxic) apoE4 expression may increase susceptibility to diverse neurological diseases involving excitotoxic mechanisms.

[1]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[2]  D. Geschwind,et al.  Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease , 2009, Nature Medicine.

[3]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[4]  Brian Spencer,et al.  The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. , 2008, The Journal of clinical investigation.

[5]  Yadong Huang,et al.  Intron-3 Retention/Splicing Controls Neuronal Expression of Apolipoprotein E in the CNS , 2008, The Journal of Neuroscience.

[6]  E. Masliah,et al.  Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat , 2007, Experimental Neurology.

[7]  J. Kelsoe,et al.  Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice , 2007, Genes, brain, and behavior.

[8]  Yadong Huang Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. , 2006, Current opinion in drug discovery & development.

[9]  M. Christiansen,et al.  The association between apolipoprotein E and multiple sclerosis , 2006, European journal of neurology.

[10]  David Walker,et al.  Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus , 2006, The Journal of Neuroscience.

[11]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Deyn,et al.  Dose dependent effect of APOE ɛ4 on behavioral symptoms in frontal lobe dementia , 2006, Neurobiology of Aging.

[13]  R. Mahley,et al.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Masliah,et al.  β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[15]  J. Haines,et al.  Apolipoprotein E controls the risk and age at onset of Parkinson disease , 2004, Neurology.

[16]  Tony Wyss-Coray,et al.  Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.

[17]  R. Mahley,et al.  Astroglial Regulation of Apolipoprotein E Expression in Neuronal Cells , 2004, Journal of Biological Chemistry.

[18]  L. Mucke,et al.  Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Mucke,et al.  Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.

[20]  D. Holtzman,et al.  Apolipoprotein E, amyloid, and Alzheimer disease. , 2002, Molecular interventions.

[21]  L. Mucke,et al.  Androgens Protect against Apolipoprotein E4-Induced Cognitive Deficits , 2002, The Journal of Neuroscience.

[22]  D. Holtzman,et al.  Behavioral Phenotyping of GFAP-ApoE3 and -ApoE4 Transgenic Mice: ApoE4 Mice Show Profound Working Memory Impairments in the Absence of Alzheimer's-like Neuropathology , 2001, Experimental Neurology.

[23]  R. Mahley,et al.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Bedlack,et al.  Apolipoprotein E and neuromuscular disease: a critical review of the literature. , 2000, Archives of neurology.

[26]  Raja Parasuraman,et al.  Genetics and visual attention: Selective deficits in healthy adult carriers of the ɛ4 allele of the apolipoprotein E gene , 2000 .

[27]  A. Fagan,et al.  No effect of apolipoprotein E on neuronal cell death due to excitotoxic and apoptotic agents in vitro and neonatal hypoxic ischaemia in vivo , 2000, The European journal of neuroscience.

[28]  A. Fagan,et al.  Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model , 2000, Annals of neurology.

[29]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[30]  L. Mucke,et al.  Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease , 2000, Neuroscience.

[31]  L. Mucke,et al.  Alzheimer's disease: Apolipoprotein E and cognitive performance , 2000, Nature.

[32]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Roses,et al.  Apolipoprotein E Expression by Neurons Surviving Excitotoxic Stress , 1999, Neurobiology of Disease.

[34]  W. März,et al.  Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions , 1999, Acta Neuropathologica.

[35]  Matthias Orth,et al.  Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/− Mice: Isoform-Specific Effects on Neurodegeneration , 1999, The Journal of Neuroscience.

[36]  R. Mahley,et al.  Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.

[37]  J. D. Smith,et al.  Human apolipoprotein E allele-specific brain expressing transgenic mice , 1998, Neurobiology of Aging.

[38]  L. Mucke,et al.  Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[40]  G. Murray,et al.  Association of apolipoprotein E polymorphism with outcome after head injury , 1997, The Lancet.

[41]  J. Olney,et al.  Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. , 1997, Archives of neurology.

[42]  O. Steward,et al.  Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Hofman,et al.  Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. , 1997, JAMA.

[44]  A. Roses,et al.  Neurodegeneration in the Central Nervous System of apoE-Deficient Mice , 1995, Experimental Neurology.

[45]  R. Mantegna,et al.  Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Mucke,et al.  Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: In vivo comparison of distinct GFAP‐lacZ transgenes , 1995, Glia.

[47]  J. Olney,et al.  Excitotoxicity and the NMDA receptor - still lethal after eight years , 1995, Trends in Neurosciences.

[48]  M. Pericak-Vance,et al.  Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Olney Excitatory transmitter neurotoxicity , 1994, Neurobiology of Aging.

[50]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[51]  E. Masliah,et al.  Spectrum of human immunodeficiency virus–associated neocortical damage , 1992, Annals of neurology.

[52]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[53]  E. Shooter,et al.  Expression of apolipoprotein E during nerve degeneration and regeneration. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[55]  L. Mucke,et al.  Apolipoprotein E , 2007, Journal of Molecular Neuroscience.

[56]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[57]  J. Breslow,et al.  Human apolipoprotein E isoprotein subclasses are genetically determined. , 1981, American journal of human genetics.